{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T20:23:12Z","timestamp":1792959792890,"version":"4.5.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["175230"],"award-info":[{"award-number":["175230"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Patient-derived airway cell cultures are used in personalized medicine strategies for people with cystic fibrosis (pwCF) to predict potential clinical response to cystic fibrosis transmembrane conductance regulator (CFTR) modulator drugs. While bronchial epithelial cells from lung explants (HBEx) are the gold standard for CFTR functional measurements, nasal epithelial cells (HNE) are a more practical tissue source resulting in widespread use for preclinical functional platforms. HNE have so far not been rigorously validated against the gold standard for this purpose. In this study, we collected nasal and bronchial cells, and lung explants from pwCF undergoing lung transplantation as well as non-CF controls. Comparative studies in non-CF cells showed that while CFTR-mediated transepithelial currents in HNE underestimated those in HBEx, the magnitude of the CFTR modulator response was similar between CF HNE, brushed HBE (HBEb), and HBEx with significant correlation between matched HNE and HBEb from 16 pwCF. These findings confirm use of HNE as surrogate of bronchial airway for preclinical drug testing with report of drug responses in relation to the tissue-specific non-CF or baseline controls rather than as absolute results. Furthermore, CF centres offering HNE-based drug testing utilize different techniques, challenging the comparison of results between centres. We show how culture media, use of fresh or freeze-thawed cells as well as difference in Ussing technique impact the magnitude of measured CFTR function, which is why we suggest diligence in reporting of these factors when presenting CFTR modulator drug response results.<\/jats:p>","DOI":"10.3389\/fphar.2025.1651122","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T05:45:25Z","timestamp":1757051125000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Nasal cells as a bronchial cell surrogate for pre-clinical assessment of drug response in cystic fibrosis"],"prefix":"10.3389","volume":"16","author":[{"given":"Malina","family":"Barillaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Avolio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharaniyaa","family":"Balachandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan","family":"Ip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenming","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Zabner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaf","family":"Keshavjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Bear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo J.","family":"Moraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Gonska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"L119","DOI":"10.1152\/ajplung.00639.2020","article-title":"CFTR function and clinical response to modulators parallel nasal epithelial organoid swelling","volume":"321","author":"Anderson","year":"2021","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"11200","DOI":"10.1038\/s41598-023-37828-0","article-title":"Comparison of commercially available differentiation media on cell morphology, function, and anti-viral responses in conditionally reprogrammed human bronchial epithelial cells","volume":"13","author":"Awatade","year":"2023","journal-title":"Sci. Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e14603","DOI":"10.14814\/PHY2.14603","article-title":"Effect of apical chloride concentration on the measurement of responses to CFTR modulation in airway epithelia cultured from nasal brushings","volume":"8","author":"Bratcher","year":"2020","journal-title":"Physiol. Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e99385","DOI":"10.1172\/JCI.INSIGHT.99385","article-title":"Brushed nasal epithelial cells are a surrogate for bronchial epithelial CFTR studies","volume":"3","author":"Brewington","year":"2018","journal-title":"JCI Insight"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2202437","DOI":"10.1183\/13993003.02437-2022","article-title":"The French compassionate program of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant","volume":"61","author":"Burgel","year":"2023","journal-title":"Eur. Respir. J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"441","DOI":"10.4193\/Rhin21.046","article-title":"Differences and similarities between the upper and lower airway: focusing on innate immunity","volume":"59","author":"Cho","year":"2021","journal-title":"Rhinology J."},{"key":"B7","doi-asserted-by":"publisher","first-page":"8382","DOI":"10.1038\/ncomms9382","article-title":"Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosis","volume":"6","author":"Corvol","year":"2015","journal-title":"Nat. Commun."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1164\/rccm.201911-2199OC","article-title":"A single-cell atlas of the human healthy airways","volume":"202","author":"Deprez","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jcf.2020.02.006","article-title":"Amplifiers co-translationally enhance CFTR biosynthesis via PCBP1-mediated regulation of CFTR mRNA","volume":"19","author":"Dukovski","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1513\/AnnalsATS.201708-668PS","article-title":"The U.S. food and drug administration\u2019s experience with ivacaftor in cystic fibrosis. Establishing efficacy using in vitro data in lieu of a clinical trial","volume":"15","author":"Durmowicz","year":"2018","journal-title":"Ann. Am. Thorac. Soc."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e00152","DOI":"10.1002\/prp2.152","article-title":"Increased efficacy ofVX\u2010809 in different cellular systems results from an early stabilization effect of F508del\u2010CFTR","volume":"3","author":"Farinha","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"B12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1177\/2472555217729790","article-title":"Use of a high-throughput phenotypic screening strategy to identify amplifiers, a novel pharmacological class of small molecules that exhibit functional synergy with potentiators and correctors","volume":"23","author":"Giuliano","year":"2018","journal-title":"SLAS Discov."},{"key":"B13","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/J.JCF.2022.02.007","article-title":"Expression of cystic fibrosis lung disease modifier genes in human airway models","volume":"21","author":"He","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"15835","DOI":"10.1038\/s41598-019-50963-x","article-title":"Gene network approach reveals co-expression patterns in nasal and bronchial epithelium","volume":"9","author":"Imkamp","year":"2019","journal-title":"Sci. Rep."},{"key":"B16","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1385\/1-59259-185-X:115","article-title":"An in vitro model of differentiated human airway epithelia: methods for establishing primary cultures","volume-title":"Epithelial cell culture protocols","author":"Karp","year":"2002"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445\u2013Tezacaftor\u2013Ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3791\/63409","article-title":"Primary human nasal epithelial cells: biobanking in the context of precision medicine","volume":"2022","author":"Kelly","year":"2022","journal-title":"J. Vis. Exp."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2002774","DOI":"10.1183\/13993003.02774-2020","article-title":"Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator","volume":"57","author":"Laselva","year":"2021","journal-title":"Eur. Respir. J."},{"key":"B20","doi-asserted-by":"publisher","first-page":"L1063","DOI":"10.1152\/ajplung.00190.2019","article-title":"Structural and functional variations in human bronchial epithelial cells cultured in air-liquid interface using different growth media","volume":"318","author":"Leung","year":"2020","journal-title":"Am. J. Physiology-Lung Cell. Mol. Physiology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"6963","DOI":"10.1038\/S41598-020-63922-8","article-title":"Choosing the right differentiation medium to develop mucociliary phenotype of primary nasal epithelial cells in vitro","volume":"10","author":"Luengen","year":"2020","journal-title":"Sci. Rep."},{"key":"B22","doi-asserted-by":"publisher","first-page":"17971","DOI":"10.1038\/s41598-017-17952-4","article-title":"Conditionally reprogrammed primary airway epithelial cells maintain morphology, lineage and disease specific functional characteristics","volume":"7","author":"Martinovich","year":"2017","journal-title":"Sci. Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.15252\/emmm.201607137","article-title":"Orkambi\u00ae and amplifier co\u2010therapy improves function from a rare CFTR mutation in gene\u2010edited cells and patient tissue","volume":"9","author":"Molinski","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/978-1-61779-117-8_4","article-title":"Use of primary cultures of human bronchial epithelial cells isolated from cystic fibrosis patients for the pre-clinical testing of CFTR modulators","volume":"741","author":"Neuberger","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1113\/JP282143","article-title":"Correlating genotype with phenotype using CFTR-Mediated whole-cell cl\u2212 currents in human nasal epithelial cells","volume":"600","author":"Noel","year":"2022","journal-title":"J. Physiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"7375","DOI":"10.1038\/s41598-017-07504-1","article-title":"Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators","volume":"7","author":"Pranke","year":"2017","journal-title":"Sci. Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMOA1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/978-1-61779-120-8_18","article-title":"Primary epithelial cell models for cystic fibrosis research","volume":"742","author":"Randell","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.jcf.2022.04.019","article-title":"Caution advised in the use of CFTR modulator treatment for individuals harboring specific CFTR variants","volume":"21","author":"Raraigh","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B30","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1165\/rcmb.2023-0356MA","article-title":"Cell culture differentiation and proliferation conditions influence the in vitro regeneration of the human airway epithelium","volume":"71","author":"Redman","year":"2024","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"18573","DOI":"10.1038\/s41598-023-45201-4","article-title":"Exploring intrinsic variability between cultured nasal and bronchial epithelia in cystic fibrosis","volume":"13","author":"Rodenburg","year":"2023","journal-title":"Sci. Rep."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.3390\/cells9092137","article-title":"Choice of differentiation media significantly impacts cell lineage and response to CFTR modulators in fully differentiated primary cultures of cystic fibrosis human airway epithelial cells","volume":"9","author":"Saint-Criq","year":"2020","journal-title":"Cells"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.3390\/cells9092090","article-title":"Ionocytes and CFTR chloride channel expression in normal and cystic fibrosis nasal and bronchial epithelial cells","volume":"9","author":"Scudieri","year":"2020","journal-title":"Cells"},{"key":"B34","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/978-1-0716-3507-0_13","article-title":"Primary human nasal epithelial cell culture","volume":"2725","author":"Terrance","year":"2024","journal-title":"Methods Mol. Biol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"L1117","DOI":"10.1152\/ajplung.00169.2005","article-title":"Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules","volume":"290","author":"Van Goor","year":"2006","journal-title":"Am. J. Physiology-Lung Cell. Mol. Physiology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of cf airway epithelial cell function in vitro by a CFTR potentiator, VX-770","volume":"106","author":"Van Goor","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"18843","DOI":"10.1073\/pnas.1105787108","article-title":"Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809","volume":"108","author":"Van Goor","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e139983","DOI":"10.1172\/JCI.INSIGHT.139983","article-title":"Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (trikafta) combination","volume":"5","author":"Veit","year":"2020","journal-title":"JCI Insight"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/s41591-019-0468-5","article-title":"A cellular census of human lungs identifies novel cell states in health and in asthma","volume":"25","author":"Vieira Braga","year":"2019","journal-title":"Nat. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor\u2013ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N. Engl. J. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1651122\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T05:45:26Z","timestamp":1757051126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1651122\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":40,"alternative-id":["10.3389\/fphar.2025.1651122"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1651122","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,5]]},"article-number":"1651122"}}